Home » Stocks » HOOK

HOOKIPA Pharma Inc. (HOOK)

Stock Price: $12.78 USD 0.57 (4.67%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 378.04M
Revenue (ttm) 18.04M
Net Income (ttm) -41.85M
Shares Out 25.66M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $12.78
Previous Close $12.21
Change ($) 0.57
Change (%) 4.67%
Day's Open 12.14
Day's Range 12.02 - 12.85
Day's Volume 105,523
52-Week Range 5.90 - 13.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Seeking Alpha - 3 weeks ago

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease...

GlobeNewsWire - 1 month ago

NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p...

GlobeNewsWire - 1 month ago

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p...

GlobeNewsWire - 1 month ago

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus p...

Zacks Investment Research - 1 month ago

HOOKIPA (HOOK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Benzinga - 1 month ago

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biop...

Other stocks mentioned: GMDA
GlobeNewsWire - 1 month ago

NEW YORK and VIENNA, Austria, Dec. 07, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary a...

GlobeNewsWire - 1 month ago

NEW YORK and VIENNA, Austria, Nov. 30, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary a...

Benzinga - 2 months ago

Shares of HOOKIPA Pharma (NASDAQ:HOOK) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share were down 17.78% year over year to ($0.53), which missed the e...

GlobeNewsWire - 2 months ago

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary a...

GlobeNewsWire - 2 months ago

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary a...

GlobeNewsWire - 4 months ago

Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7 

GlobeNewsWire - 4 months ago

NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious di...

GlobeNewsWire - 4 months ago

NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious di...

Zacks Investment Research - 5 months ago

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 39.13% and 138.32%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

Zacks Investment Research - 5 months ago

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

Zacks Investment Research - 5 months ago

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

GlobeNewsWire - 7 months ago

NEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

GlobeNewsWire - 7 months ago

NEW YORK and VIENNA, Austria, June 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

GlobeNewsWire - 7 months ago

NEW YORK and VIENNA, Austria, June 17, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and c...

Zacks Investment Research - 7 months ago

HOOKIPA (HOOK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

HOOKIPA Pharma Inc (HOOK) delivered earnings and revenue surprises of -10.26% and -15.13%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 8 months ago

NEW YORK and VIENNA, Austria, May 14, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dise...

Zacks Investment Research - 8 months ago

HOOKIPA Pharma Inc (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.

Other stocks mentioned: VKTX
GlobeNewsWire - 1 year ago

NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

GlobeNewsWire - 1 year ago

NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

Seeking Alpha - 1 year ago

Hookipa's Technology Appears To Be A Vaccine Gamechanger Against Infectious Disease And Cancer

GlobeNewsWire - 1 year ago

Christine D. Baker has joined as Chief Business Officer  Roman Necina, PhD, will join as Chief Technology Officer 

GlobeNewsWire - 1 year ago

NEW YORK and VIENNA, Austria, Sept. 19, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious di...

GlobeNewsWire - 1 year ago

NEW YORK and VIENNA, Austria, Aug. 29, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious dis...

Seeking Alpha - 1 year ago

Hookipa stated that the FDA allowed the clearance of an IND needed to begin a phase 1/2 study to treat HPV-positive cancers using HB-201.

24/7 Wall Street - 1 year ago

Hookipa Pharma Inc. (NASDAQ: HOOK) is not a household name, or even well-known within the biotech industry, but it is making waves on Friday after the firm announced an update from the U.S.

Market Watch - 1 year ago

Hookipa Pharma Inc. shares jumped 40% in late trading Thursday after the company announced that the Food and Drug Administration approved a study of the company's immunotherapy approach to cer...

About HOOK

HOOKIPA Pharma, a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The compa... [Read more...]

Industry
Biotechnology
IPO Date
Apr 18, 2019
CEO
Joern Aldag
Employees
85
Stock Exchange
NASDAQ
Ticker Symbol
HOOK
Full Company Profile

Financial Performance

In 2019, HOOKIPA Pharma's revenue was $11.94 million, an increase of 56.53% compared to the previous year's $7.63 million. Losses were -$43.04 million, 165.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for HOOKIPA Pharma stock is "Buy." The 12-month stock price forecast is 22.29, which is an increase of 74.41% from the latest price.

Price Target
$22.29
(74.41% upside)
Analyst Consensus: Buy